Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Randomized, Open-Label Study Comparing Triple Therapy Versus Sildenafil Dose Optimization in Patients With Pulmonary Arterial Hypertension Using COMPERA 2.0 Risk Stratification as the Primary Outcome

NCT07713914 is registered in ClinicalTrials.gov with University of Sao Paulo General Hospital as lead sponsor.

NCT NCT07713914
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07713914 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Randomized, Open-Label Study Comparing Triple Therapy Versus Sildenafil Dose Optimization in Patients With Pulmonary Arterial Hypertension Using COMPERA 2.0 Risk Stratification as the Primary Outcome
Lead sponsor
University of Sao Paulo General Hospital
Phase
Phase 4
Overall status
Recruiting
Start date
July 22, 2026
Completion date
December 31, 2028
Enrollment
196 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

pulmonary arterial hypertension (pah)